How did Cyclerion Therapeutics Inc (CYCN) surprise investors with its report?

Cyclerion Therapeutics Inc [CYCN] stock is trading at $3.60, down -32.33%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYCN shares have gain 63.64% over the last week, with a monthly amount glided 38.46%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Cyclerion Therapeutics Inc [NASDAQ: CYCN] stock has seen the most recent analyst activity on October 20, 2021, when Truist initiated its Buy rating and assigned the stock a price target of $14. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on September 24, 2021, and set its price target to $7. On June 03, 2019, Credit Suisse initiated with a Neutral rating.

Cyclerion Therapeutics Inc [CYCN] stock has fluctuated between $1.27 and $9.47 over the past year. Cyclerion Therapeutics Inc [NASDAQ: CYCN] shares were valued at $3.60 at the most recent close of the market.

Analyzing the CYCN fundamentals

Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -30.54%, Pretax Profit Margin comes in at -27.22%, and Net Profit Margin reading is -27.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.55 and Total Capital is -0.72.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.79 points at the first support level, and at 1.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.96, and for the 2nd resistance point, it is at 6.31.

Ratios To Look Out For

For context, Cyclerion Therapeutics Inc’s Current Ratio is 5.07. Further, the Quick Ratio stands at 5.07, while the Cash Ratio is 4.1. Considering the valuation of this stock, the price to sales ratio is 34.76, the price to book ratio is 1.11.

Transactions by insiders

Recent insider trading involved Slate Path Capital LP, 10% Owner, that happened on Nov 21 ’24 when 0.36 million shares were sold.

Related Posts